Skip to main content
SpringerLink
Log in

Patients’ appraisal of side effects in quality of life assessments of immunosuppressive regimens

  • Chapter
Immunosuppression under Trial

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 31))

Abstract

Quality of life has emerged as an important outcome measure in health care over the past two decades, and is increasingly used to evaluate treatment options. Indeed, understanding the quality of life implications of a new treatment modality in addition to studying its effects in terms of incidence of complications and mortality rate provides a more sophisticated and balanced view of treatment effects. Quality of life data offer a more complete understanding of the benefit/burden ratio associated with medical treatments in terms of patients’ physical, emotional/mental and social functioning.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Office of Technology Assessment. Recombinant Human Erythropoietin: Payment Options for Medicare. Publication No. OTA-H-451. Washington, DC: United States Government Printing Office, 1990.

    Google Scholar 

  2. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300: 573–578.

    Article  Google Scholar 

  3. Raeburn JM, Rootman I. Quality of life and health promotion. In: Renwick R, Brown I, Nagler M, editors. Quality of Life in Health Promotion and Rehabilitation. Thousand Oaks: Sage Publications; 1996: 14–25.

    Google Scholar 

  4. Felce D. Defining and applying the concept of quality of life. J. Intellect. Disabil. Res. 1997; 41: 126–135.

    Article  Google Scholar 

  5. World Health Organization. Constitution in Basic Documents. Geneva: WHO, 1948.

    Google Scholar 

  6. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N. Engl. J. Med. 1996; 334: 35–40.

    Article  Google Scholar 

  7. Dew MA, Regalski JM, Switzer GE, Allen AS. Quality of life in organ transplantation: Effects on adult recipients and their families. In: Trzepacz PT, DiMartini A, editors. Transplantation Psychiatry: Issues for the 90s. New York: Cambridge University Press, in press.

    Google Scholar 

  8. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care. 1994; 32: 40–66.

    CAS  Google Scholar 

  9. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 1992; 30: 473–483.

    Article  Google Scholar 

  10. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc. Sci. Med. 1981; 15: 221–229.

    CAS  Google Scholar 

  11. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care. 1981; 19: 787–805.

    Article  CAS  Google Scholar 

  12. Dew MA, Switzer GE, Goycoolea, JM et al: Does transplantation produce quality of life benefits? Transplantation. 1997; 64: 1261–1273.

    Article  PubMed  CAS  Google Scholar 

  13. Bernabeu M, Krupp P, Wiskott E. Long-term safety of cyclosporine in renal transplant recipients: worldwide experience. Transplant. Proc. 1993; 25: 17–19.

    CAS  Google Scholar 

  14. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleveland Clin. J. Med. 1994; 61: 308–313.

    CAS  Google Scholar 

  15. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation. 1987; 43: 197–204.

    Article  PubMed  CAS  Google Scholar 

  16. Morris-Stiff G, Ostrowski K, Balaji V et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transplant. Int. 1998; 11: S334–S336.

    Google Scholar 

  17. Pasha TM, Wiesner RH, Dahlke LM, Porayko MK, Krom RAF. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Liver. Transplant. Surg. 1998; 4: 410–415.

    CAS  Google Scholar 

  18. Seale JP, Compton MR. Side-effects of corticosteroid agents. Med. J. Aust. 1986; 144: 139–142.

    CAS  Google Scholar 

  19. Taylor DO. The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. Curr. Opin. Cardiol. 1997; 12: 161–165.

    Article  CAS  Google Scholar 

  20. Rhodes VA, Watson PM. Symptom distress, the concept: past and present. Semin. Oncol. 1987; 3: 242–247.

    CAS  Google Scholar 

  21. Lough ME, Lindsey AM, Shinn JA, Stotts NA. Life satisfaction following heart transplantation. J. Heart Transplant. 1985; 4: 446–449.

    PubMed  CAS  Google Scholar 

  22. Lough ME, Lindsey AM, Shinn JA, Stotts NA. Impact of symptom frequency and symptom distress on self-reported quality of life in heart transplant recipients. Heart Lung. 1987; 16: 193–200.

    PubMed  CAS  Google Scholar 

  23. Jones BM, Taylor FJ, Wright OM et al. Quality of life after heart transplantation in patients assigned to double-or triple-drug therapy. J. Heart Transplant. 1990; 9: 392–396.

    PubMed  CAS  Google Scholar 

  24. De Geest S, Abraham I, Dunbar-Jacob J, Vanhaecke J. The significance of noncompliance in the etiology of acute late rejections in the heart transplant population. Circulation. 1997; 96: 1–15.

    Google Scholar 

  25. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient non-compliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant. Proc. 1988; 10 (suppl.3): 63–69.

    Google Scholar 

  26. Schweitzer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Non-compliance in organ transplant recipients. Transplantation. 1990; 49: 374–377.

    Article  Google Scholar 

  27. Sketris I, Grobler M, West M, Gerus S. Factors affecting compliance with cyclosporine in adult renal transplant recipients. Transplant. Proc. 1994; 26: 2538–2541.

    CAS  Google Scholar 

  28. De Geest S, Borgermans L, Gemoets H et al. Incidence, determinants, and consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995; 59: 340–347.

    PubMed  Google Scholar 

  29. Moons P, De Geest S, Abraham I, Van Cleemput J, Vanhaecke J. Symptom experience associated with maintenance immunosuppression after heart transplantation: patients’ appraisal of side effects. Heart Lung. 1998; 27: 315–325.

    Article  PubMed  CAS  Google Scholar 

  30. Teixeira de Barros C, Cabrita J, Pena JR. Self-report of symptom frequency and symptom distress in kidney transplant recipients. In: Pharmacoepidemiology and Drug Safety. Abstract supplement; 1998 August 16–19; Berlin, Germany. New York: Wiley, 1998.

    Google Scholar 

  31. Jalowiec A, Grady KL, White-Williams C et al. Symptom distress three months after heart transplantation. J. Heart Lung. Transplant. 1997; 16: 604–614.

    PubMed  CAS  Google Scholar 

  32. De Geest S, Moons P, Versteven K, Vlaminck H, Moens G, Waer M. Validity and reliability of the Modified Transplant Symptom Occurrence and Symptom Distress Scale. In: Transplant 98 Book of Abstracts; 1998 July 12–17; Montréal, Canada. The Transplantation Society, 1998.

    Google Scholar 

  33. Gijsbers van Wijk CM, Kolk AM, van den Bosch WJ, van den Hoogen HJ. Male and female morbidity in general practice: the nature of sex differences. Soc. Sci. Med. 1992; 35: 665–678.

    Google Scholar 

  34. Lieban RW. Gender and symptom sensitivity: report on a Philippine study. Am. J. Orthopsychiatry. 1985; 55: 446–450.

    Article  PubMed  CAS  Google Scholar 

  35. Verbrugge LM. Gender and health: an update on hypotheses and evidence. J. Health Soc. Behay. 1985; 26: 156–182.

    Article  CAS  Google Scholar 

  36. Bross IDJ. How to use ridit analysis. Biometrics. 1958; 14: 18–38.

    Article  Google Scholar 

  37. Sermeus W, Delesie L. Ridit analysis on ordinal data. West. J. Nurs. Res. 1996; 18: 351–359.

    CAS  Google Scholar 

  38. Foley TC, Davis CP, Conway PA. Liver transplant recipients - self-report of symptom frequency, symptom distress, quality of life. Transplant. Proc. 1989; 21: 2417–2418.

    CAS  Google Scholar 

  39. Baumann LJ, Young CJ, Egan JJ. Living with a heart transplant: long-term adjustment. Transplant. Int. 1992; 5: 1–8.

    CAS  Google Scholar 

Download references

Authors
  1. P. Moons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Fairchild
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. De Geest
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

P. Cochat J. Traeger C. Merieux M. Derchavane

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Moons, P., Fairchild, S., De Geest, S. (1999). Patients’ appraisal of side effects in quality of life assessments of immunosuppressive regimens. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4643-2_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5960-2

  • Online ISBN: 978-94-011-4643-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation